Vertex Pharmaceuticals ( VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...
The drug, Journavx by Vertex Pharmaceuticals ... also submitted data from a 250-person study that assessed the drug’s safety and tolerability in patients with pain from surgery, trauma or ...
JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration ... pain relief and a safety profile "without addictive ...
Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration ... Journavx can provide pain relief and a safety profile "without addictive potential." ...
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX ... for the treatment of adults with moderate-to-severe acute pain. The drug, which will be marketed under the brand name JOURNAVX, is the first ...